Burns J W & Co. Inc. NY Sells 467 Shares of Zoetis Inc. (NYSE:ZTS)

Burns J W & Co. Inc. NY cut its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 1.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 31,158 shares of the company’s stock after selling 467 shares during the period. Burns J W & Co. Inc. NY’s holdings in Zoetis were worth $5,272,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the business. Blue Bell Private Wealth Management LLC lifted its holdings in shares of Zoetis by 222.5% in the fourth quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock valued at $25,000 after purchasing an additional 89 shares in the last quarter. Webster Bank N. A. raised its holdings in shares of Zoetis by 89.1% in the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after purchasing an additional 82 shares during the last quarter. Independence Bank of Kentucky boosted its holdings in Zoetis by 371.4% during the fourth quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock worth $33,000 after purchasing an additional 130 shares during the last quarter. Private Wealth Management Group LLC purchased a new stake in Zoetis in the 4th quarter valued at about $33,000. Finally, Ramirez Asset Management Inc. bought a new position in shares of Zoetis during the 3rd quarter worth approximately $35,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

ZTS traded down $3.10 during trading on Friday, reaching $173.36. 4,189,580 shares of the company were exchanged, compared to its average volume of 2,374,760. The company has a quick ratio of 1.94, a current ratio of 3.33 and a debt-to-equity ratio of 1.30. The company has a market cap of $79.10 billion, a price-to-earnings ratio of 33.40, a P/E/G ratio of 2.74 and a beta of 0.88. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92. The company’s 50-day moving average is $168.69 and its two-hundred day moving average is $178.81.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, beating analysts’ consensus estimates of $1.34 by $0.04. The company had revenue of $2.19 billion during the quarter, compared to analyst estimates of $2.14 billion. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. Zoetis’s revenue was up 9.5% compared to the same quarter last year. During the same period last year, the business earned $1.31 earnings per share. Research analysts forecast that Zoetis Inc. will post 5.76 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 4th. Investors of record on Thursday, July 18th will be given a $0.432 dividend. The ex-dividend date of this dividend is Thursday, July 18th. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.00%. Zoetis’s dividend payout ratio (DPR) is presently 33.33%.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $151.17, for a total transaction of $139,529.91. Following the completion of the sale, the executive vice president now owns 14,800 shares of the company’s stock, valued at $2,237,316. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.16% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on ZTS. HSBC decreased their price target on Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a research report on Wednesday, May 8th. The Goldman Sachs Group decreased their price objective on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a report on Monday, May 6th. Stifel Nicolaus decreased their price target on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, April 30th. Piper Sandler reiterated an “overweight” rating and issued a $195.00 price objective (down previously from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. Finally, Barclays lowered their target price on Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 23rd. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $211.75.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.